Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAECs Transplantation for Primary Ovarian Failure
NCT02912104Phase 1Completed
- Sponsor
- International Peace Maternity and Child Health Hospital
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human amniotic epithelial stem cells in primary ovarian insufficiency (POI), sponsored by International Peace Maternity and Child Health Hospital. Primary endpoint: Safety and Tolerability assessed by Adverse Events at 150 days. Started Jun 2020; status: completed.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
primary ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT02912104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912104.